<DOC>
	<DOCNO>NCT02464878</DOCNO>
	<brief_summary>Patients meet study entry criterion receive 1-3 infusion ( ) vitro culture islet . Patients receive three time week AAT infusion peri-transplant period three week .</brief_summary>
	<brief_title>Multicenter Trial Effect AAT Islet Transplant Engraftment Durability After Renal Transplant</brief_title>
	<detailed_description />
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Male female subject age 18 70 year . Subjects able provide write informed consent comply procedure study protocol . Subjects must one follow payment mechanisms place : 1 . Medicare , 2 . A thirdparty insurer agrees , via preauthorization , pay participation study , 3 . Another mechanism payment ( selfpay , hospital , university , donation , etc . ) participation study . Clinical history compatible T1D disease onset &lt; 40 year age insulindependence ≥ 5 year time enrollment . Absent stimulate cpeptide ( &lt; 0.3 ng/mL ) response MMTT [ Boost® 6 mL/kg body weight ( BW ) maximum 360 mL ; another product equivalent caloric nutrient content may substitute Boost® ] measure 60 90 min start consumption . Subjects ≥ 3 month postrenal transplant take appropriate calcineurin inhibitor ( CNI ) base maintenance immunosuppression ( [ tacrolimus alone conjunction sirolimus , mycophenolate mofetil , myfortic , azathioprine ; cyclosporine conjunction sirolimus , mycophenolate mofetil , myfortic ] ± Prednisone ≤ 10 mg/day ) . Stable renal function define creatinine one third great average creatinine determination perform 3 previous month prior islet transplantation , rejection , obstruction infection rule . Subjects meet one option follow criterion eligible transplantation : Reduced awareness hypoglycemia manifest Clarke score 4 measure upon study enrollment least one episode severe hypoglycemia 12 month prior study enrollment . A subject must reduce awareness hypoglycemia manifest Clarke score 4 least 1 episode severe hypoglycemia ; Any subject meeting hypoglycemia option must HbA1c &gt; 7.5 % . Weight 100 kg body mass index ( BMI ) &gt; 33 kg/m2 . Insulin requirement &gt; 1.0 U/kg/day , &gt; 60 U/day total , &lt; 15 U/day . Other ( nonkidney ) organ transplant except prior fail pancreatic graft graft failure attribute thrombosis within first 4 week technical reason require graft pancreatectomy ; graft pancreatectomy occur 6 month ago . Untreated unstable proliferative diabetic retinopathy . Blood Pressure : SBP &gt; 160 mmHg DBP &gt; 100 mmHg despite treatment antihypertensive agent . Calculated GFR ≤ 40 mL/min/1.73 m2 use subject 's measure serum creatinine Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) equation1 . Strict vegetarian ( vegan ) exclude estimate GFR ≤ 35 mL/min/1.73 m2 . 7 . Proteinuria ( albumin/creatinine ratio ACr &gt; 300mg/g ) new onset since kidney transplantation . Calculated panelreactive antiHLA antibody &gt; 50 % . Subjects calculate panel reactive antiHLA antibody ≤ 50 % exclude follow detect : Positive crossmatch , Islet donordirected antiHLA antibody detect Luminex Single Antigen/specificity bead assay include weakly reactive antibody would detect flow crossmatch , Antibodies renal donor ( i.e . presume de novo ) . For female subject : Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study 4 month discontinuation . For male subject : intent procreate duration study within 4 month discontinuation unwillingness use effective measure contraception . Oral contraceptive , Norplant® , DepoProvera® , barrier device spermicide acceptable contraceptive method ; condom use alone acceptable . Presence history active infection include hepatitis B , hepatitis C , HIV , tuberculosis ( TB ) . Subjects laboratory evidence active infection exclude even absence clinical evidence active infection . Negative screen EpsteinBarr virus ( EBV ) IgG determination time screen previous kidney transplant . Invasive aspergillus , histoplasmosis , coccidoidomycosis infection within last year . Any history malignancy except completely resect squamous basal cell carcinoma skin . Known active alcohol substance abuse . Any coagulopathy medical condition require longterm anticoagulant therapy ( e.g . warfarin ) islet transplantation ( lowdose aspirin treatment [ 325 mg PO ] allow ) subject international normalized ratio ( INR ) &gt; 1.5 . The use Plavix allow conjunction mini laparotomy procedure time islet transplant . Severe coexist cardiac disease , characterize one condition : Recent MI ( within past 6 month ) ; Evidence ischemia functional cardiac exam within last year ; Left ventricular ejection fraction &lt; 30 % ; Valvular disease require replacement prosthetic valve . Persistent serum glutamicoxaloacetic transaminase ( SGOT [ AST ] ) , serum glutamate pyruvate transaminase ( SGPT [ ALT ] , ) alkaline phosphatase total bilirubin , value &gt; 1.5 time normal upper limit exclude subject . Active infection ( except mild skin nail fungal infection ) . Acute chronic pancreatitis . Active peptic ulcer disease , symptomatic gallstone , portal hypertension . Use investigational agent within 4 week enrollment . Administration live attenuate vaccine ( ) within 2 month enrollment . Any medical condition , opinion investigator , interfere safe participation trial . ( Cancer screening perform per current American Cancer Society guideline ) . Positive screen BK virus polymerase chain reaction ( PCR ) perform time screening . A kidney transplant patient type 1 diabetes HbA1c &lt; 7.5 history severe hypoglycemia . Selective severe IgA deficiency ( level &lt; 57 mg/dL ) AAT deficiency ( define &lt; 1.0ng/mg AAT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>